提供支持According to PEdaily.cn, Chengdu Hyperway Pharmaceuticals ("Hyperway") has recently announced the completion of another angel round of tens of millions yuan. In May 2019, Hyperway obtained tens of millions yuan in its first angel round financing led by Si Chuan Venture Capital with participation from Xiamen Yiyuan Pharmaceutical Technology Co., Ltd. It has raised nearly 100 million yuan in funding.
Hyperway is a startup biotech company founded in January 2019 by a group of high caliper biotech entrepreneurs and industry veterans, located in Chengdu high tech Development Zone. The company is committed to discover and develop new medicines to address unmet medical needs using breakthroughs in science and technology. Within a short period of time, Hyperway has developed pipelines covering many therapeutic areas, including oncology, pain and central nervous system (CNS). Most of them are still in the early development stages.
In terms of innovative drug research and development, up to now, Hyperway has nine pipelines covering anti-tumor, CNS, autoimmune system, analgesia, anti-depression, and other fields. The team has basically identified the clinical candidate in one of the projects, with the potential of being a kind of best-in-class drug. It is expected to be applied for clinical certification in the near future.
As for generic drugs, Hyperway has four product pipelines covering anti-infection, cardiovascular and others.
Hyperway also has four pipelines in the R&D of fine chemicals. One of the projects has significant advantages such as the simple production process and low pollution, product purity up to 99.9%, and so on.
Hyperway's core team members have many years of scientific and management experience in leading global or domestic pharmaceutical companies, such as Bayer, Sanofi, Merck, Wuxi PharmaTech, ChemPartner and Amgen. Among their achievements, some are inventers of several first-in-class new drug candidates that are being evaluated in clinical trials.
渝公网安备 50011202502165号
